Shots:

• The first patient has been dosed in a P-III clinical trial to evaluate the efficacy of uproleselan + CT vs CT alone in 140 adult patients with r/r AML and who are eligible to receive induction CT at ~20 blood cancer clinical research centers across China. The therapy is discovered and developed by GlycoMimetics
• The 1EPs of the study is OS and secondary outcomes include the rate and duration of remission, and reduce the rate of oral mucositis
• Uproleselan is the E-selectin-targeted inhibitor & has received BTD from the US FDA and NMPA for AML patients. Additionally, Apollomics gets the rights for uproleselan from GlycoMimetics in Greater China

Click here to­ read full press release/ article 

Ref: Businesswire | Image: Apollomics